Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer.

Core Viewpoint - Pfizer announced an acquisition of Metsera, offering $47.50 per share, with an additional $22.50 per share contingent on the achievement of specific drug milestones [1] Company Summary - Pfizer is set to pay a total of $70 per share for Metsera if certain performance milestones are met, indicating a strategic investment in Metsera's drug pipeline [1]